Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
<p><strong>Background:</strong> Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia i...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1797106564751949824 |
|---|---|
| author | DiNardo, CD Schuh, AC Stein, EM Montesinos, P Wei, AH de Botton, S Zeidan, AM Fathi, AT Kantarjian, HM Bennett, JM Frattini, MG Martin-Regueira, P Lersch, F Gong, J Hasan, M Vyas, P Döhner, H |
| author_facet | DiNardo, CD Schuh, AC Stein, EM Montesinos, P Wei, AH de Botton, S Zeidan, AM Fathi, AT Kantarjian, HM Bennett, JM Frattini, MG Martin-Regueira, P Lersch, F Gong, J Hasan, M Vyas, P Döhner, H |
| author_sort | DiNardo, CD |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia ineligible for intensive chemotherapy.</p>
<p><strong>Methods:</strong> This open-label, phase 1b/2 trial was done at 43 clinical sites in 12 countries (the USA, Germany, Canada, the UK, France, Spain, Australia, Italy, the Netherlands, Portugal, Switzerland, and South Korea). Eligible patients were aged 18 years or older and had newly diagnosed, mutant-IDH2 acute myeloid leukaemia, and an Eastern Cooperative Oncology Group performance status of 0–2. In the phase 1b dose-finding portion, patients received oral enasidenib 100 mg/day or 200 mg/day in continuous 28-day cycles, plus subcutaneous azacitidine 75 mg/m2 per day for 7 days of each cycle. In phase 2, patients were randomly assigned (2:1) via an interactive web response system to enasidenib plus azacitidine or azacitidine-only, stratified by acute myeloid leukaemia subtype (de novo or secondary). The primary endpoint in the phase 2 portion was the overall response rate in the intention-to-treat population at a prespecified interim analysis (Aug 20, 2019) when all patients had at least 1 year of follow-up. Safety was assessed in all patients who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov, NCT02677922, and is ongoing.</p>
<p><strong>Findings:</strong> Between June 3, 2016, and Aug 2, 2018, 322 patients were screened and 107 patients with mutant-IDH2 acute myeloid leukaemia were enrolled. At data cutoff for the interim analysis, 24 patients (including two from the phase 1 portion) were still receiving their assigned treatment. Six patients were enrolled in the phase 1b dose-finding portion of the trial and received enasidenib 100 mg (n=3) or 200 mg (n=3) in combination with azacitidine. No dose-limiting toxicities occurred and the enasidenib 100 mg dose was selected for phase 2. In phase 2, 101 patients were randomly assigned to enasidenib plus azacitidine (n=68) or azacitidine only (n=33). Median age was 75 years (IQR 71–78). 50 (74%; 95% CI 61–84) patients in the enasidenib plus azacitidine combination group and 12 (36%; 20–55) patients in the azacitidine monotherapy group achieved an overall response (odds ratio 4·9 [95% CI 2·0–11·9]; p=0·0003). Common treatment-related grade 3 or 4 adverse events with enasidenib plus azacitidine were thrombocytopenia (25 [37%] of 68 vs six [19%] of 32 in the azacitidine-only group), neutropenia (25 [37%] vs eight [25%]), anaemia (13 [19%] vs seven [22%]), and febrile neutropenia (11 [16%] vs five [16%]). Serious treatment-related adverse events were reported in 29 (43%) patients in the combination group and 14 (44%) patients in the azacitidine-only group; serious treatment-related adverse events occurring in more than 5% of patients in either group were febrile neutropenia (nine [13%] in the combination group vs five [16%] in the azacitidine-only group), differentiation syndrome (seven [10%] vs none), and pneumonia (three [4%] vs two [6%]). No treatment-related deaths were reported.</p>
<p><strong>Interpretation:</strong> Combination enasidenib plus azacitidine was well tolerated and significantly improved overall response rates compared with azacitidine monotherapy, suggesting that this regimen can improve outcomes for patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia.</p> |
| first_indexed | 2024-03-07T07:02:46Z |
| format | Journal article |
| id | oxford-uuid:205cd829-d2ee-4297-8f03-218a06ed95d6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:02:46Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:205cd829-d2ee-4297-8f03-218a06ed95d62022-04-19T09:08:14ZEnasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:205cd829-d2ee-4297-8f03-218a06ed95d6EnglishSymplectic ElementsElsevier2021DiNardo, CDSchuh, ACStein, EMMontesinos, PWei, AHde Botton, SZeidan, AMFathi, ATKantarjian, HMBennett, JMFrattini, MGMartin-Regueira, PLersch, FGong, JHasan, MVyas, PDöhner, H<p><strong>Background:</strong> Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia ineligible for intensive chemotherapy.</p> <p><strong>Methods:</strong> This open-label, phase 1b/2 trial was done at 43 clinical sites in 12 countries (the USA, Germany, Canada, the UK, France, Spain, Australia, Italy, the Netherlands, Portugal, Switzerland, and South Korea). Eligible patients were aged 18 years or older and had newly diagnosed, mutant-IDH2 acute myeloid leukaemia, and an Eastern Cooperative Oncology Group performance status of 0–2. In the phase 1b dose-finding portion, patients received oral enasidenib 100 mg/day or 200 mg/day in continuous 28-day cycles, plus subcutaneous azacitidine 75 mg/m2 per day for 7 days of each cycle. In phase 2, patients were randomly assigned (2:1) via an interactive web response system to enasidenib plus azacitidine or azacitidine-only, stratified by acute myeloid leukaemia subtype (de novo or secondary). The primary endpoint in the phase 2 portion was the overall response rate in the intention-to-treat population at a prespecified interim analysis (Aug 20, 2019) when all patients had at least 1 year of follow-up. Safety was assessed in all patients who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov, NCT02677922, and is ongoing.</p> <p><strong>Findings:</strong> Between June 3, 2016, and Aug 2, 2018, 322 patients were screened and 107 patients with mutant-IDH2 acute myeloid leukaemia were enrolled. At data cutoff for the interim analysis, 24 patients (including two from the phase 1 portion) were still receiving their assigned treatment. Six patients were enrolled in the phase 1b dose-finding portion of the trial and received enasidenib 100 mg (n=3) or 200 mg (n=3) in combination with azacitidine. No dose-limiting toxicities occurred and the enasidenib 100 mg dose was selected for phase 2. In phase 2, 101 patients were randomly assigned to enasidenib plus azacitidine (n=68) or azacitidine only (n=33). Median age was 75 years (IQR 71–78). 50 (74%; 95% CI 61–84) patients in the enasidenib plus azacitidine combination group and 12 (36%; 20–55) patients in the azacitidine monotherapy group achieved an overall response (odds ratio 4·9 [95% CI 2·0–11·9]; p=0·0003). Common treatment-related grade 3 or 4 adverse events with enasidenib plus azacitidine were thrombocytopenia (25 [37%] of 68 vs six [19%] of 32 in the azacitidine-only group), neutropenia (25 [37%] vs eight [25%]), anaemia (13 [19%] vs seven [22%]), and febrile neutropenia (11 [16%] vs five [16%]). Serious treatment-related adverse events were reported in 29 (43%) patients in the combination group and 14 (44%) patients in the azacitidine-only group; serious treatment-related adverse events occurring in more than 5% of patients in either group were febrile neutropenia (nine [13%] in the combination group vs five [16%] in the azacitidine-only group), differentiation syndrome (seven [10%] vs none), and pneumonia (three [4%] vs two [6%]). No treatment-related deaths were reported.</p> <p><strong>Interpretation:</strong> Combination enasidenib plus azacitidine was well tolerated and significantly improved overall response rates compared with azacitidine monotherapy, suggesting that this regimen can improve outcomes for patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia.</p> |
| spellingShingle | DiNardo, CD Schuh, AC Stein, EM Montesinos, P Wei, AH de Botton, S Zeidan, AM Fathi, AT Kantarjian, HM Bennett, JM Frattini, MG Martin-Regueira, P Lersch, F Gong, J Hasan, M Vyas, P Döhner, H Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title | Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title_full | Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title_fullStr | Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title_full_unstemmed | Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title_short | Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial |
| title_sort | enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed mutant idh2 acute myeloid leukaemia ag221 aml 005 a single arm phase 1b and randomised phase 2 trial |
| work_keys_str_mv | AT dinardocd enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT schuhac enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT steinem enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT montesinosp enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT weiah enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT debottons enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT zeidanam enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT fathiat enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT kantarjianhm enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT bennettjm enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT frattinimg enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT martinregueirap enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT lerschf enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT gongj enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT hasanm enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT vyasp enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial AT dohnerh enasidenibplusazacitidineversusazacitidinealoneinpatientswithnewlydiagnosedmutantidh2acutemyeloidleukaemiaag221aml005asinglearmphase1bandrandomisedphase2trial |